Maravai Lifesciences Holdings (MRVI) Capital Expenditures (2020 - 2026)

Maravai Lifesciences Holdings' Capital Expenditures history runs 7 years deep, the most recent figure standing at $4.4 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 209.41% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $16.2 million (down 42.17% YoY), while the FY2025 annual figure was $13.1 million, down 55.66% from the prior year.
• Capital Expenditures was $4.4 million for Q1 2026 at Maravai Lifesciences Holdings, down from $12.2 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $46.0 million in Q3 2023 to a low of -$5.1 million in Q2 2023.
• Historically, Capital Expenditures has averaged $7.6 million across 5 years, with a median of $4.4 million in 2026.
• Biggest YoY gain for Capital Expenditures was 1862.11% in 2023; the steepest drop was 407.34% in 2023.
• A 5-year view of Capital Expenditures shows it stood at $15.3 million in 2022, then advanced by 9.86% to $16.8 million in 2023, then plunged by 65.18% to $5.8 million in 2024, then jumped by 109.15% to $12.2 million in 2025, then sank by 63.73% to $4.4 million in 2026.
• The last three Capital Expenditures figures came in at $4.4 million (Q1 2026), $12.2 million (Q4 2025), and -$806000.0 (Q3 2025), per Business Quant data.